Get started
Author

Meimei Si

Observed names: Mei-Mei Si, Mei-mei Si
ORCID: 0000-0001-6564-0058
Observed ORCID: 0000-0001-6564-0058
OpenAlex ID: A5022225580
Insulin releasing and alpha-glucosidase inhibitory activity of ethyl acetate fraction of Acorus calamus in vitro and in vivo
2010 · Mei-mei Si, Jian-shu Lou, et al. · Journal of Ethnopharmacology · 123
Effects of phenolic-rich litchi (Litchi chinensis Sonn.) pulp extracts on glucose consumption in human HepG2 cells
2014 · Qiang Lv, Meimei Si, et al. · Journal of Functional Foods · 63
Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE)
2024 · Yuankai Shi, Jianhua Chen, et al. · Journal of Thoracic Oncology · 53
PDF
Effects and molecular mechanisms of the antidiabetic fraction of Acorus calamus L. on GLP-1 expression and secretion in vivo and in vitro
2015 · Yun-Xi Liu, Mei-Mei Si, et al. · Journal of Ethnopharmacology · 39
Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial
2022 · Yuankai Shi, Jian Fang, et al. · Signal Transduction and Targeted Therapy · 37
PDF
Neohesperidin Exerts Lipid-Regulating Effects in vitro and in vivo via Fibroblast Growth Factor 21 and AMP-Activated Protein Kinase/Sirtuin Type 1/Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1α Signaling Axis
2017 · Haoshu Wu, Yunxi Liu, et al. · Pharmacology · 34
Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)
2023 · Yuankai Shi, Jianhua Chen, et al. · BMC Medicine · 29
PDF
Synthesis and biological evaluation of novel benzyl-substituted (S)-phenylalanine derivatives as potent dipeptidyl peptidase 4 inhibitors
2013 · Yang Liu, Meimei Si, et al. · Bioorganic & Medicinal Chemistry · 23
A novel indole derivative compound GY3 improves glucose and lipid metabolism via activation of AMP-activated protein kinase pathway
2012 · Meimei Si, Youyou Yan, et al. · European Journal of Pharmacology · 14
QL1604 plus paclitaxel-cisplatin/carboplatin in patients with recurrent or metastatic cervical cancer: an open-label, single-arm, phase II trial
2024 · Cheng Fang, Yun Zhou, et al. · Journal of Gynecologic Oncology · 13
Hyperglycemia decreases anti-cancer efficiency of adriamycin via AMPK pathway
2018 · Xiaqing Xu, Meimei Si, et al. · Endocrine Related Cancer · 6
PDF
Abstract 5551: QLS31905, an anti-claudin 18.2/CD3 bispecific antibody for claudin 18.2-positive gastric cancer
2022 · Jiahua Jiang, Meimei Si, et al. · Cancer Research · 3
Hyperglycemia decreases anti-cancer efficiency of adriamycin via AMPK pathway
2020 · Xiaqing Xu, Meimei Si, et al. · Endocrine Related Cancer · 3
PDF
Efficacy and safety of iruplinalkib (WX‑0593) on non‑small cell lung cancer with SPECC1L‑ALK fusion: A case report
2023 · Quan Zhang, Jialin Lv, et al. · Experimental and Therapeutic Medicine · 2
PDF
A phase Ib/II, open-label, multicenter study to evaluate the safety, efficacy, and pharmacokinetics/pharmacodynamics of αvβ3/5 integrin and neuropilin-1 targeting peptide LSTA1 in patients with metastatic pancreatic ductal adenocarcinoma.
2023 · Jianming Xu, Zuoxing Niu, et al. · Journal of Clinical Oncology · 2
PDF
A phase II trial of ALK/ROS1 tyrosine kinase inhibitor WX-0593 (iruplinalkib) in ALK-positive and crizotinib-resistant advanced non–small cell lung cancer.
2022 · Yuankai Shi, Jianhua Chen, et al. · Journal of Clinical Oncology · 2
Generation of a potent anti-PD-L1-CD47 bispecific antibody with a strong therapeutic and safety profile for cancer immunotherapy
2023 · Irene Tang, Lauren Schwimmer, et al. · Frontiers in Drug Discovery · 1
PDF
Design, Synthesis and Biological Evaluation of Novel Imidazolone Derivatives as Dipeptidyl Peptidase 4 Inhibitors
2013 · Yang Liu, Chaoyi Jiang, et al. · Medicinal Chemistry · 1
Phase Ib/II Study of the CEND-1 (Targeting αV-Integrin and Neuropilin-1) with nab-Paclitaxel/Gemcitabine in First-Line Treatment of Metastatic Pancreatic Cancer
2025 · Juan Li, Shengjie Sun, et al. · SSRN Electronic Journal
Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors
2024 · Guihong Yang, Yimei Wang, et al. · Clinical and Translational Science
PDF
Abstract 2894: QL401, a dual PD-L1/CD47 blocker effective against both solid and hematological malignancies with improved blood safety
2022 · Irene Tang, Lauren Schwimmer, et al. · Cancer Research
Works count: 21
Citation count: 448
H-index: 10
I10-index: 10
Year
Topic
Type